<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000328" GROUP_ID="NEONATAL" ID="332199091720452728" MERGED_FROM="" MODIFIED="2008-10-30 21:20:35 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Short title (no longer in use): Elective HFJV versus CV in preterm infants&lt;/p&gt;&lt;p&gt;do not remove&lt;/p&gt;&lt;p&gt;CL 1/03 (update)&lt;/p&gt;&lt;p&gt;sent 10/05&lt;br&gt;Sent to Loni Dec 6/06&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 12:20:25 -0400" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0002" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-10-30 21:20:35 +0100" MODIFIED_BY="Diane Haughton">
<TITLE>Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants</TITLE>
<CONTACT MODIFIED="2008-10-30 21:20:35 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="19687" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tushar</FIRST_NAME><LAST_NAME>Bhuta</LAST_NAME><SUFFIX>MBBS FRACP MD DCh MMed(Clin Epi)</SUFFIX><POSITION>Staff Specialist</POSITION><EMAIL_1>tbhuta@med.usyd.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neonatal Medicine</DEPARTMENT><ORGANISATION>Royal North Shore Hospital</ORGANISATION><ADDRESS_1>Pacific Highway</ADDRESS_1><ADDRESS_2>St Leonards</ADDRESS_2><CITY>Sydney</CITY><ZIP>2065</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 9926 5586</PHONE_1><PHONE_2>0412 980 130</PHONE_2><FAX_1>+61 2 9926 6651</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-10-30 21:20:35 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="19687" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tushar</FIRST_NAME><LAST_NAME>Bhuta</LAST_NAME><SUFFIX>MBBS FRACP MD DCh MMed(Clin Epi)</SUFFIX><POSITION>Staff Specialist</POSITION><EMAIL_1>tbhuta@med.usyd.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neonatal Medicine</DEPARTMENT><ORGANISATION>Royal North Shore Hospital</ORGANISATION><ADDRESS_1>Pacific Highway</ADDRESS_1><ADDRESS_2>St Leonards</ADDRESS_2><CITY>Sydney</CITY><ZIP>2065</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 9926 5586</PHONE_1><PHONE_2>0412 980 130</PHONE_2><FAX_1>+61 2 9926 6651</FAX_1></ADDRESS></PERSON><PERSON ID="4691" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Henderson-Smart</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>dhs@mail.usyd.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>NSW Centre for Perinatal Health Services Research</DEPARTMENT><ORGANISATION>Queen Elizabeth II Research Institute</ORGANISATION><ADDRESS_1>Building DO2</ADDRESS_1><ADDRESS_2>University of Sydney</ADDRESS_2><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 93517318</PHONE_1><PHONE_2>+61 2 93517728</PHONE_2><FAX_1>+61 2 93517742</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-30 21:20:35 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Minor update: 04/11/02&lt;/p&gt;&lt;p&gt;New studies sought but none found: 02/10/02&lt;/p&gt;&lt;p&gt;Reformatted: 17/09/99&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 12:14:46 -0400" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="4" MONTH="11" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="10" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="1998"/>
</DATES>
<WHATS_NEW NOTES="&lt;p&gt;This updates the review 'Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants' published in The Cochrane Library, Issue 2, 1998. The searches have been updated to October 2002. No new trials have been found.&lt;/p&gt;">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="16" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="16" MONTH="1" YEAR="1998"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NSW Centre for Perinatal Health Services Research, University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Neonatology, Royal North Shore Hospital, Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Royal Prince Alfred Hospital, Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-16 12:15:03 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-16 12:15:00 -0400" MODIFIED_BY="[Empty name]">Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-16 12:15:03 -0400" MODIFIED_BY="[Empty name]">
<P>High frequency jet ventilation may help reduce chronic lung disease in preterm babies but adverse effects are unclear. Lung disease is a major cause of death in very low birth weight babies. Chronic lung disease (CLD) following mechanical ventilation for babies with breathing difficulties is also common. It is possible that the low gas exchange in newborns during breathing may help cause chronic lung disease. Elective high frequency jet ventilation (HFJV) is one type of mechanically assisted breathing method that may improve gas exchange in neonates without injuring the lung. The review of trials found there may be benefits of HFJV but not enough evidence of adverse effects. More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Pulmonary disease continues to be the major cause of mortality and morbidity in very low birth weight infants. Chronic lung disease (CLD) following mechanical ventilation for respiratory distress syndrome (RDS) is still a problem despite increased use of antenatal steroids and surfactant replacement therapy. Immaturity, barotrauma, volutrauma and oxygen toxicity are thought to be important factors in the cause of CLD. There is some evidence from animal and adult human studies that adequate ventilation can be achieved at lower pressures when using high frequency jet ventilation (HFJV, about 200-400 breaths per minute) compared to conventional ventilation (CV, 30-80 breaths per minute). </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to determine whether the elective (commencing soon after initiation of mechanical ventilation) use of high frequency jet ventilation, as compared to conventional ventilation in preterm infants with respiratory distress syndrome (RDS), would decrease the incidence of chronic lung disease without adverse effects.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Randomized trials from MEDLINE were identified by means of MeSH and text words 'high frequency ventilation', 'high frequency jet ventilation', 'jet ventilation' from the years 1980 to October 2002. The EMBASE database (1982-2002), the Oxford Database of Perinatal Trials, the Neonatal Trials Register of the Neonatal Review Group of the Cochrane Collaboration and The Cochrane Library (Issue 3, 2002) were also accessed. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized controlled trials of elective high frequency jet ventilation versus conventional ventilation in preterm infants born at less than 35 weeks GA or with a birth weight less than 2000 gms with respiratory distress were included in the systematic review. Trials which used HFJV to 'rescue' preterm infants due to severe respiratory distress usually beyond 24 hours, and trials that used HFJV for a mandatory time period and then switched back to CV, were not included in this review.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The standard methods of the Neonatal Cochrane Review Group were used, including independent trial assessment and data extraction. Data were analysed using relative risk (RR) and risk difference (RD). From 1/RD the number needed to treat (NNT) for benefits and number needed to harm (NNH) for adverse outcomes were calculated.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Overall analysis of the three trials showed that HFJV is associated with a reduction in CLD at 36 weeks postmenstrual age in survivors [RR 0.58 (0.34, 0.98), RD -0.138 (-0.268, -0.007), NNT 7 (4, 90)]. The use of home oxygen therapy was evaluated in only one study (Keszler 1997) and a lower rate was found in the HFJV group [RR 0.24 (0.07, 0.79), RD -0.176 (-0.306, -0.047), NNT 5 (3, 21)]. Overall there was a trend towards an increase in the risk of PVL in the HFJV group, which was not significant. Subgroup analyses shows a significant increase in risk of PVL in the trial by Wiswell 1996 [RR 5.0 (1.19, 21.04), RD 0.250 (0.069, 0.431), NNH 4.0 (2.3,14.5)] where a 'low volume strategy' was the standard protocol for HFJV. In the other trial by Keszler 1997, where the intention was to use a 'high volume strategy', there was no significant difference in the incidence of PVL, RR 0.42 (0.14, 1.30). </P>
<P>In the overall analysis, there were no significant differences in the incidence of neonatal mortality, IVH all grades or in grades 3 or 4 IVH. In the subgroup where 'low volume strategy' was used there was a non-significant trend toward an increase in risk of IVH all grades and grades 3 or 4 IVH.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The overall analysis shows a benefit in pulmonary outcomes in the group electively ventilated with HFJV. Of concern is the significant increase in acute brain injury in one trial which used lower mean airway pressures when ventilating with HFJV. There are as yet no long term pulmonary or neurodevelopmental outcomes from any of the trials. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<P>Pulmonary disease continues to be the major cause of mortality and morbidity in very low birth weight infants. Chronic lung disease (CLD) following mechanical ventilation for respiratory distress syndrome (RDS) is still a problem despite increased use of antenatal steroids and surfactant replacement therapy. In addition to immaturity, barotrauma, volutrauma and oxygen toxicity during intermittent positive pressure ventilation are thought to be important factors in the cause of CLD (<LINK REF="REF-Ehrenkranz-1992" TYPE="REFERENCE">Ehrenkranz 1992</LINK>, <LINK REF="REF-Jobe-2000" TYPE="REFERENCE">Jobe 2000</LINK>).</P>
<P>There is evidence from animal studies (<LINK REF="REF-Barringer-1982" TYPE="REFERENCE">Barringer 1982</LINK>, <LINK REF="REF-Carlon-1983" TYPE="REFERENCE">Carlon 1983</LINK>, <LINK REF="REF-Hoff-1981" TYPE="REFERENCE">Hoff 1981</LINK>) and adult studies (<LINK REF="REF-Carlon-1981" TYPE="REFERENCE">Carlon 1981</LINK> and <LINK REF="REF-Turnbull-1981" TYPE="REFERENCE">Turnbull 1981</LINK>) that high frequency jet ventilation (HFJV, 200 - 400 breaths per minute) may reduce the severity of lung injury during mechanical ventilation. Observational studies (<LINK REF="REF-Pokora-1983" TYPE="REFERENCE">Pokora 1983</LINK>, <LINK REF="REF-Carlo-1984" TYPE="REFERENCE">Carlo 1984</LINK>) suggested that HFJV may improve gas exchange in neonates with respiratory failure with lower pressures than conventional ventilation (CV).</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review was to determine whether the elective use of high frequency jet ventilation (HFJV) as compared to conventional ventilation in preterm infants with RDS who were mechanically ventilated would decrease the incidence of chronic lung disease without adverse effects.</P>
<P>The following 'a priori' subgroup analyses were planned:</P>
<P>1) Trials with and without surfactant replacement therapy. Surfactant replacement therapy would be expected to increase alveolar recruitment, attentuate RDS and thus could alter treatment effects.</P>
<P>2) High and low volume ventilator strategies on HFJV. Ventilator strategies aimed at maintaining effective lung volume (high volume strategy, HVS) such as use of high mean airway pressures, manoeuvres to recruit alveolar volume after suctioning and weaning of FiO2 before pressure would be expected to have better responses to treatment than those using a low volume strategy (LVS).<BR/> <BR/>3) Infants at different gestational ages and birth weight, as they have different baseline rates of CLD and neurologic injury, may respond differently to the treatment.</P>
<P>4) Trials with and without adequate humidification. Different rates of necrotizing tracheitis and its consequences would be expected due to treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomized controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Preterm infants born at less than 35 weeks gestational age or with a birth weight of less than 2000 gms with pulmonary dysfunction, principally due to RDS and who were receiving IPPV.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Included in the systematic review were trials in preterm infants which compared elective HFJV versus CV, with randomization early in the course of RDS soon after mechanical ventilation was commenced. Such trials were classified as ' Elective'. Trials were classified as 'Rescue', and excluded from this review, when patients were randomized after failure to adequately ventilate on CV or when complications of CV developed or were likely to develop. Trials that used HFJV for a mandatory short time period and then switched back to CV were not included in this review. The words 'conventional ventilation' (CV) implied time-cycled, pressure limited ventilation with respiratory rates of approximately 30-80/min.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The following are the main outcomes sought in this review.</P>
<P>1) Mortality by 28-30 days, and before discharge.<BR/>2) Chronic lung disease defined as; a) supplemental oxygen or MV at 28d; or b) supplemental oxygen or MV at 36 weeks post-menstrual age (PMA)<BR/>3) Pulmonary air leak syndromes defined as presence of any of the following: pneumothorax, pulmonary interstitial emphysema or pneumoperitonium.<BR/>4) Intraventricular hemorrhages; a) all grades; b) grades 3 or 4<BR/>5) Periventricular leukomalacia<BR/>6) Periventricular echodensities<BR/>7) Necrotizing tracheobronchitis or subglottic stenosis<BR/>8) Pulmonary and neurodevelopmental outcomes in childhood</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>Search was made of MEDLINE by means of the MeSH and text words, 'high frequency ventilation', 'high frequency jet ventilation', 'jet ventilation' from the years 1980 to October 2002; of EMBASE, and trials register held by the Neonatal Review Group of the Cochrane Collaboration (The Cochrane Library, Issue 3, 2002) and Oxford Database of Perinatal Trials. Information was also obtained from experts in the field and from cross references in published articles. Proceedings of Society for Pediatric Research/American Pediatric Society meetings were hand searched (1991-2002). </P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<P>The standard review methods of the Neonatal Review Group as documented in the Cochrane Library were used. This included independent quality assessment by the second author. Completeness of follow-up in this review is considered acceptable if less than 10% of subjects are excluded after randomization.</P>
<P>Additional data were obtained from <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>.</P>
<P>Methods used to collect data from the included trials:<BR/>Each author extracted data separately, then compared and resolved differences. Additional data were requested from authors as required.</P>
<P>Methods used to synthesize the data:<BR/>The standard method of the Neonatal Review Group was used, including for categorical data, use of relative risk (RR) and risk difference (RD). From 1/RD the number needed to treat (NNT) for benefits or number needed to harm (NNH) for adverse effects and their 95% CI's were calculated. For continuous data, standardized mean difference with 95% CI was used.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<P>Five randomized trials were identified. Three (<LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK>, <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK> and <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>) were included in the systematic review. One trial (<LINK REF="STD-Carlo-1987" TYPE="STUDY">Carlo 1987</LINK>) was not included since even though patients were randomized early, the intervention of HFJV was only for 48 hours after which they were switched back to conventional ventilation. Some of the results of this trial are discussed. One rescue trial (<LINK REF="STD-Keszler-1991" TYPE="STUDY">Keszler 1991</LINK>) was also excluded.</P>
<P>In two trials the intention was to use a lower mean airway pressure (LVS) when switching from CV to HFJV (<LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK>, <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>) while the third trial (<LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>) the intention was to use a higher mean airway pressure (HVS).</P>
<P>Gestational age is normally calculated as postmenstrual age (PMA) at birth and together with postnatal age, is used here to define O2 dependency at 36 weeks. <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK> and <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK> used the term postconceptual age but did not define it. This needs author clarification.</P>
<P>Surfactant was administered to infants in two trials (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>, <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>).</P>
<P>Details of each study are given in the Included Studies Table and in the references.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<P>Details of the methodological quality of each study are available in the Characteristics of Included Studies table. All trials concealed the randomization process and the treatment could not be blinded in any study. There were some post randomization losses to follow up in two trials (7% in <LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK>, 9% in <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>). Some infants were not assessed for the outcomes of IVH and PVL in the <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK> trial (6% in HFJV group and 9% in CV group). The primary outcomes of interest (CLD, IVH and PVL) were assessed blind in two studies (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK> and <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>) and this was unclear in the third (<LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<P>Chronic Lung Disease (CLD)<BR/>In the overall analysis, there is a non-significant trend towards a reduction in the incidence of CLD at 28 days. There is a similar non-significant trend towards a reduction of CLD in the subgroup analyses where surfactant replacement therapy was used and also where a LVS was used.</P>
<P>CLD at 36 weeks PMA is significantly reduced in the two trials that assessed this outcome (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK> and <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>) both of which were also in the surfactant subgroup [summary RR 0.58 (0.34, 0.98); RD 0.138 (-0.268, -0.007), NNT 7 (4, 90)]. This outcome is also reduced in the trial (<LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>) where high volume strategy was used [RR 0.50 (0.27, 0.92); RD -0.204 (-0.374, -0.034), NNT 7 (4, 90)]. The one trial (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>) that used a low volume strategy when on HFJV and reported CLD at 36 weeks PMA found no difference.</P>
<P>The use of home oxygen was assessed in only one study (<LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>). The number of patients on home oxygen was found to be lower in the HFJV group [RR 0.24 (0.07, 0.79); RD -0.176 (-0.306, -0.047), NNT 5 (3, 21)].</P>
<P>Air Leak Syndromes<BR/>There is no significant difference in incidence of air leak syndromes in the individual trials or in the overall analysis.</P>
<P>Neonatal Mortality<BR/>There is no significant difference in neonatal mortality in any individual trial, in the overall analysis, or in the subgroup analyses.</P>
<P>Intraventricular Hemorrhage (IVH)<BR/>There are no significant differences in the incidence of IVH of all grades in any individual trial or in the overall analysis. In the subgroup where low volume strategy was used there is a trend towards an increase in incidence of IVH. There are no significant differences in incidence of the more severe grades of IVH (3 or 4) in any individual trials or in the overall analyses [summary RR 1.37 ( 0.79, 2.37)]. In the subgroup where a low volume strategy was used only one trial reported IVH by grade (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>) and there is a non-significant trend towards an increase in grades 3 or 4 IVH. In the trial by <LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK> progression to IVH grades 2 to 4 was reported as 9/21 in HFJV group and 7/21 in the CV group. However these figures include two patients in the HFJV group and seven patients in the CV group without initial head ultrasound who also developed grade 2 to 4 IVH. Thus these results were not included in the meta-analysis.</P>
<P>Periventricular Leukomalacia (PVL)<BR/>This outcome was reported in two studies (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>, <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>). Overall there is a non-significant trend towards an increase in risk [summary RR 1.24 (0.59, 2.61)] of PVL. In the one trial where a high volume strategy was intended (<LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>) there is a trend towards a reduction in risk of PVL [RR 0.42 (0.14, 1.30)]. In the subgroup where a low volume strategy was used, only one trial (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>) reported PVL and there is a significant increase [RR 5.0 (1.19, 21.04), RD 0.250 (0.069, 0.0431), NNH 4.0 (2.3,14.5)].</P>
<P>Periventricular Echodensities (PVE)<BR/>This outcome was assessed only in the <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK> trial and no significant difference was found.</P>
<P>Continuous Data Outcomes<BR/>The following continuous outcomes were reported from the eligible trials and have been included after reviewing the studies. <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK> also reported medians and ranges for the continuous data since the data were not normally distributed.</P>
<P>Days in supplemental oxygen was assessed by all the trials as means and SD. The pooled results show a non-significant trend towards a decrease with HFJV. <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK> also reported the medians and ranges of days in supplemental oxygen [HFJV 37 (3-160) and CV 46 (3-167)].</P>
<P>Days on Mechanical ventilation (MV) is available from all three trials as means and SD. The pooled data gave a non-significant trend towards an increase in the days on MV. <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK> also reported the data as medians and ranges [HFJV 20 (3-96) and CV 26 (2-82)].</P>
<P>
<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK> reported a non-significant trend towards a decrease in length of hospital stay. <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK> reported the medians and ranges as 71 (24-198) for the HFJV group and 76 (33-167) for the CV group, which were not significantly different.</P>
<P>Two of the planned subgroup analyses could not be performed. There were no outcome data presented by gestational age or birth weight despite stratification at randomization in two of the studies (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>, <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>). Lack of humidification is now thought to be only of historical importance and was not a reported problem in any of the included trials.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<P>It is possible that there are other trials which have not been published or have been published in a language not covered by this systematic review. This is a potential source of bias.</P>
<P>Pulmonary Outcomes<BR/>Overall this review suggests that the elective use of HFJV for preterm infants with RDS is associated with a reduction in measures of CLD such as oxygen or ventilator dependency at 36 weeks PMA and use of oxygen therapy at home. However, there are no long term pulmonary follow-up data from these studies. In the excluded trial (<LINK REF="STD-Carlo-1987" TYPE="STUDY">Carlo 1987</LINK>) there were no differences in the incidence of CLD between the groups. During the 48 hour study period, 4/20 in the HFJV group and 8/20 in the CV developed one or more air leaks, this was, however, not significant.</P>
<P>Neurological Outcomes<BR/>Although there was no significant difference in short term brain injury in the overall analysis, subgroup analysis indicated that brain injury was more common when a 'low volume strategy' for HFJV was used (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>). The <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK> trial intended to use a 'high volume strategy' but this was actually used in only 56% of infants. Post hoc analyses indicated that the rate of acute brain injury such as grades 3 or 4 IVH was higher in the group who actually received a 'low volume strategy' (high volume strategy 3/34, 8.8% vs low volume strategy 6/27, 22.2%). There were no differences in the incidence of IVH developing during the 48 hour study period in the trial by <LINK REF="STD-Carlo-1987" TYPE="STUDY">Carlo 1987</LINK>.</P>
<P>In the overall analysis there was a trend towards an increase in the incidence of PVL which was not significant. However, in the trial by <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK> there was a significant increase in the incidence of PVL. In the report of this trial the logistic regression analysis of ventilator assignment showed that HFJV was independently associated with PVL. Hypocarbia was found not to be independently associated with any adverse outcomes in this trial although observational studies have suggested that marked hypocarbia is associated with an increased risk of cystic PVL (<LINK REF="REF-Calvert-1986" TYPE="REFERENCE">Calvert 1986</LINK>, <LINK REF="REF-Graziani-1992" TYPE="REFERENCE">Graziani 1992</LINK>, <LINK REF="REF-Fujimoto-1994" TYPE="REFERENCE">Fujimoto 1994</LINK>).</P>
<P>The cause of acute neurological injury in some infants on HFJV is uncertain. This outcome has been reported from a single centre and the generalizability of this result is uncertain. The possible association with the use of a 'low volume strategy' during high frequency ventilation here has also been suggested in the review of trials evaluating high frequency oscillatory ventilation (<LINK REF="REF-Henderson_x002d_Smart-2002" TYPE="REFERENCE">Henderson-Smart 2002</LINK>). The reason for this apparent association is unknown. To resolve the issue a randomized controlled trial comparing high and low volume strategies would be required. This is unlikely to be done given the current preference to use the 'high volume strategy', a strategy which has been recommended on the basis of animal studies (<LINK REF="REF-Froese-1991" TYPE="REFERENCE">Froese 1991</LINK>).</P>
<P>Benefits in terms of a reduction in CLD, where on an average seven infants would be needed to be treated to prevent CLD at 36 weeks in one infant, may be associated with increased risk of PVL, where for every four infants treated there would be one additional infant with PVL. This adverse effect is a 'worst case' scenario as it is based on one study (<LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>), and the other study (<LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>) reporting this outcome showed a trend toward a reduction in PVL. Until these differences can be clarified it remains possible that the risks of elective HFJV may outweigh the benefits.</P>
<P>It is of concern that there were no long term neurodevelopmental outcomes available from any of these trials.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This review suggests that there may be benefits of elective HFJV in terms of reduction in risk of CLD at 28 days and 36 weeks PMA and at discharge. Of concern is the significant increase in adverse neurological outcomes in one of the trials which used lower mean airway pressures when ventilating with HFJV. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future trials in populations at high risk of CLD, such as those born at less than 28 weeks or with a birthweight less than 1000 gms, are needed to clarify the safety and beneficial effects of elective HFJV. Long term pulmonary and neurological outcomes should be measured.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We wish to acknowledge Dr. M. Keszler for providing us with additional data.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Both authors participated in the development of the protocol. Tushar Bhuta carried out the literature searches. Both authors reviewed the trials and extracted the data. Tushar Bhuta entered the data into RevMan and wrote the review with editorial input from David Henderson-Smart.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-16 12:20:25 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-16 12:16:01 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-10-16 12:15:47 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Carlo-1990" MODIFIED="2008-10-16 12:15:35 -0400" MODIFIED_BY="[Empty name]" NAME="Carlo 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-10-16 12:15:35 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlo WA, Siner B, Chatburn RL, Robertson S, Martin RJ</AU>
<TI>Early randomized intervention with high-frequency jet ventilation in respiratory distress syndrome</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>117</VL>
<PG>765-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keszler-1997" MODIFIED="2008-10-16 12:15:43 -0400" MODIFIED_BY="[Empty name]" NAME="Keszler 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-10-16 12:15:43 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Keszler M, Modanlou HD, Brudno DS, Clark FI, Cohen RS, Ryan RM, Kaneta MK, Davis JM. Multicenter controlled clinical trial of high frequency jet ventilation in preterm infants with uncomplicated respiratory distress syndrome. Pediatrics 1997;(4)100:593-597.&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 12:15:43 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keszler M, Modanlou HD, Brudno DS, Clark FI, Cohen RS, Ryan RM, Kaneta MK, Davis JM</AU>
<TI>Multicenter controlled clinical trial of high frequency jet ventilation in preterm infants with uncomplicated respiratory distress syndrome</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<NO>4</NO>
<PG>593-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiswell-1996" MODIFIED="2008-10-16 12:15:47 -0400" MODIFIED_BY="[Empty name]" NAME="Wiswell 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-16 12:15:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiswell TE, Graziani LJ, Kornhauser MS, Cullen J, Merton DA, McKee L, Spitzer AR</AU>
<TI>High-Frequency jet ventilation in the early management of respiratory distress syndrome is associated with a greater risk for adverse outcomes</TI>
<SO>Pediatrics</SO>
<YR>1996</YR>
<VL>98</VL>
<PG>1035-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-16 12:16:01 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Carlo-1987" MODIFIED="2008-10-16 12:15:54 -0400" MODIFIED_BY="[Empty name]" NAME="Carlo 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-10-16 12:15:54 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlo WA, Chatburn RL, Martin RJ</AU>
<TI>Randomised trial of high frequency jet ventilation versus conventional ventilation in respiratory distress syndrome</TI>
<SO>Journal of Pediatrics</SO>
<YR>1987</YR>
<VL>110</VL>
<PG>275-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keszler-1991" MODIFIED="2008-10-16 12:16:01 -0400" MODIFIED_BY="[Empty name]" NAME="Keszler 1991" YEAR="">
<REFERENCE MODIFIED="2008-10-16 12:16:01 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Keszler M, Donn SM, Bucciarelli RL, et al. Multicentre controlled trial comparing high-frequency jet ventilation and conventional ventilation in newborn infants with pulmonary interstitial emphysema. J Pediatr. 1991;119:85-93.&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 12:16:01 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keszler M, Donn SM, Bucciarelli RL, et al</AU>
<TI>Multicentre controlled trial comparing high-frequency jet ventilation and conventional ventilation in newborn infants with pulmonary interstitial emphysema</TI>
<SO>Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>119</VL>
<PG>85-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-16 12:20:25 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-16 12:20:25 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Barringer-1982" MODIFIED="2008-10-16 12:16:15 -0400" MODIFIED_BY="[Empty name]" NAME="Barringer 1982" TYPE="JOURNAL_ARTICLE">
<AU>Barringer M, Meredith J, Prough D et al: Effectiveness of high frequency jet ventilation in management of experimental bronchopulmonary fistula</AU>
<SO>American Journal of Surgery</SO>
<YR>1982</YR>
<VL>48</VL>
<PG>610-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calvert-1986" MODIFIED="2008-10-16 12:16:25 -0400" MODIFIED_BY="[Empty name]" NAME="Calvert 1986" TYPE="JOURNAL_ARTICLE">
<AU>Calvert SA, Hoskins EM, Fong KW, et al</AU>
<TI>Etiological factors associated with the development of periventricular leukomalacia</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1986</YR>
<VL>76</VL>
<PG>254-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlo-1984" MODIFIED="2008-10-16 12:16:36 -0400" MODIFIED_BY="[Empty name]" NAME="Carlo 1984" TYPE="JOURNAL_ARTICLE">
<AU>Carlo WA, Chatburn RL, Martin RJ et al</AU>
<TI>Decrease in airway pressure during high-frequency jet ventilation in infants with respiratory distress syndrome</TI>
<SO>Journal of Pediatrics</SO>
<YR>1984</YR>
<VL>101-107</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlon-1981" NAME="Carlon 1981" TYPE="JOURNAL_ARTICLE">
<AU>Carlon G, Kahn R, Howland W et al: Clinical experience with high frequency jet ventilation</AU>
<SO>Crit Care Med</SO>
<YR>1981</YR>
<VL>9</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlon-1983" MODIFIED="2008-10-16 12:16:49 -0400" MODIFIED_BY="[Empty name]" NAME="Carlon 1983" TYPE="JOURNAL_ARTICLE">
<AU>Carlon GC, Griffin J, Cole R, et al: High frequency jet ventilation in experimental airway disruption</AU>
<SO>Critical Care Medicine</SO>
<YR>1983</YR>
<VL>11</VL>
<PG>353-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ehrenkranz-1992" NAME="Ehrenkranz 1992" NOTES="&lt;p&gt;Ehrenkranz RA, Mercurio MR. Bronchopulmonary dysplasia. In:Sinclair JC, Bracken MB, ed; Effective care of the newborn infant. New York: Oxford University Press, 1992.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Ehrenkranz RA, Mercurio MR</AU>
<TI>Bronchopulmonary dysplasia</TI>
<SO>Effective care of the newborn infant</SO>
<YR>1992</YR>
<ED>Sinclair JC, Bracken MB</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Froese-1991" MODIFIED="2008-10-16 12:17:01 -0400" MODIFIED_BY="[Empty name]" NAME="Froese 1991" TYPE="JOURNAL_ARTICLE">
<AU>Froese AB, Bryan AC</AU>
<TI>Reflections on the HIFI trial</TI>
<SO>Pediatrics</SO>
<YR>1991</YR>
<VL>87</VL>
<PG>565-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fujimoto-1994" MODIFIED="2008-10-16 12:17:12 -0400" MODIFIED_BY="[Empty name]" NAME="Fujimoto 1994" NOTES="&lt;p&gt;Fujimoto S, Togari H, Yamaguchi N et al. Hypocarbia and cystic periventricular leukomalacia in premature infants. Arch Dis Child. 1994;71:F107-F110.&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 12:17:12 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Fujimoto S, Togari H, Yamaguchi N et al</AU>
<TI>Hypocarbia and cystic periventricular leukomalacia in premature infants</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1994</YR>
<VL>71</VL>
<PG>F107-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graziani-1992" MODIFIED="2008-10-16 12:17:19 -0400" MODIFIED_BY="[Empty name]" NAME="Graziani 1992" TYPE="JOURNAL_ARTICLE">
<AU>Graziani LJ, Spitzer AR, Mitchell DG et al</AU>
<TI>Mechanical ventilation in preterm infants: neurosonographic and developmental studies</TI>
<SO>Pediatrics</SO>
<YR>1992</YR>
<VL>90</VL>
<PG>515-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson_x002d_Smart-2002" MODIFIED="2008-10-16 12:20:25 -0400" MODIFIED_BY="[Empty name]" NAME="Henderson-Smart 2002" NOTES="&lt;p&gt;Bhuta T, Henderson-Smart DJ. Elective high frequency oscillatory ventilation vs conventional ventilation in preterm infants with acute pulmonary dysfunction. In: Sinclair J, Bracken M, Soll RF, Horbar JD, eds. Neonatal Module of The Cochrane Database of Systematic Reviews. Available in The Cochrane Library [database on disk and CD Rom]. The Cochrane Collaboration; Oxford: Update Software; 1996.&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 12:20:25 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Henderson-Smart DJ, Bhuta T, Cools F, Offringa M</AU>
<TI>Elective high frequency oscillatory ventilation vs conventional ventilation in preterm infants with acute pulmonary dysfunction (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-10-16 12:20:25 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-16 12:20:25 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000104"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hoff-1981" NAME="Hoff 1981" NOTES="&lt;p&gt;Hoff B, Smith R, Wilson E et al: High frequency ventilation during bronchopleural fistula. Anesthesiology 1981;55:A71.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hoff B, Smith R, Wilson E et al</AU>
<TI>High frequency ventilation during bronchopleural fistula</TI>
<SO>Anesthesiology</SO>
<YR>1981</YR>
<VL>55</VL>
<PG>A71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jobe-2000" MODIFIED="2008-10-16 12:17:44 -0400" MODIFIED_BY="[Empty name]" NAME="Jobe 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jobe AH, Ikegami M</AU>
<TI>Lung development and function in preterm infants in the surfactant treatment era</TI>
<SO>Annual Review of Physiology</SO>
<YR>2000</YR>
<VL>62</VL>
<PG>825-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuban-1994" MODIFIED="2008-10-16 12:17:58 -0400" MODIFIED_BY="[Empty name]" NAME="Kuban 1994" NOTES="&lt;p&gt;Kuban KCK, Leviton A. Cerebral palsy. N Engl J Med. 1994;330:188-195.&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 12:17:58 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kuban KCK, Leviton A</AU>
<TI>Cerebral palsy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>188-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pokora-1983" NAME="Pokora 1983" TYPE="JOURNAL_ARTICLE">
<AU>Pokora T, Bing D, Mammel M, Boros S</AU>
<TI>Neonatal high frequency jet ventilation</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>72</VL>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turnbull-1981" MODIFIED="2008-10-16 12:18:21 -0400" MODIFIED_BY="[Empty name]" NAME="Turnbull 1981" NOTES="&lt;p&gt;Turnbull A, Carlon G, Howland W et al: High frequency jet ventilation in major airway or pulmonary disruption. Ann Thorac Surg 1981;32(5):468-74.&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 12:18:21 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Turnbull A, Carlon G, Howland W et al</AU>
<TI>High frequency jet ventilation in major airway or pulmonary disruption</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1981</YR>
<VL>32</VL>
<NO>5</NO>
<PG>468-74</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-10-16 12:19:38 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bhuta-1998" MODIFIED="2008-10-16 12:19:38 -0400" MODIFIED_BY="[Empty name]" NAME="Bhuta 1998" NOTES="&lt;p&gt;This review should be cited as: Bhuta T, Henderson-Smart DJ. Elective high frequency jet ventilation versus conventional ventilation for respiratory &lt;br&gt;distress syndrome in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-16 12:19:38 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Bhuta T, Henderson-Smart DJ</AU>
<TI>Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-16 12:19:38 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-16 12:19:38 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000328"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Carlo-1990">
<CHAR_METHODS>
<P>Single centre<BR/>Concealment at randomization - Yes<BR/>Blinding of intervention - No<BR/>Complete followup - Yes ( 93%)<BR/>Blinding of outcome - Can't tell<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Forty-five preterm infants less than 24 hours of age with RDS and stratified into 3 groups; 1000-1250g, 1251-1500g, 1501-2000g<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>HFJV, PIP and Paw decreased by 20% when changed to HFJV - low volume strategy (LVS), 250/min 1:3 IT:ET ratio; backup use of alternative intervention in both directions was permitted if failure documented on two consecutive ABG. <BR/>Controls were ventilated with CV on time cycled pressure limited ventilators (Bear Cub). The protocol for CV was not specified.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality at 28d, CLD at 28d, ALS, progression of IVH, success after crossover, days on MV, days on supplemental oxygen, MV at 28d.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mean age at randomization 15.5 hrs for HFJV and 14 hrs for CV; enrollment stopped when there was no difference, no surfactant used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keszler-1997">
<CHAR_METHODS MODIFIED="2008-10-16 12:15:08 -0400" MODIFIED_BY="[Empty name]">
<P>Multicentre trial; 8 centres<BR/>Blinding of randomization -Yes<BR/>Blinding of intervention - No<BR/>Completeness of followup - Yes (91%); 14 patients from one centre were excluded from the analysis as they were simultaneously enrolled in another similar trial and reported in the study by <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>. Of 130 patients analysed, 61(94%) were assessed for IVH and PVL in the HFJV group and 59(91%) in CV group.<BR/>Blinding of outcome measures -Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Reported on 130 of 144 preterm infants stratified into 3 groups 700-1500g, 1001-1250g, 1251-1500g; &lt;36weeks gestational age; &lt;20 hours of age and MV for &lt;12 hours of age;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>HFJV Bunnell Life Pulse; concurrent CV used for humidification, positive end expiratory pressure (PEEP) for alveolar recruitment and to provide intermittent sigh breaths in form of background intermittent mandatory ventilation; at the time of randomization PEEP increased and this increased Paw 0.5 to 2 cms H2O, (HVS).<BR/>CV was at rates between 30-60/min, inspiratory time of 0.3 to 0.4 sec and PEEP of 4 to 6 cms of water.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality; CLD at 28d and 36 w PCA, O2 at discharge, days in O2, IVH all grades and grades 3 or 4, PVL, Days in hospital, crossover success</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Surfactant replacement therapy used. Although high volume strategy was the intended method, some centres used a low volume strategy (44% of infants). Concerns about adverse effects in some patients in another trial forced early stoppage of the trial. Mean age at randomisation 8.3+4.2 hrs, antenatal corticosteroids usage 30% CV vs 21% HFJV</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wiswell-1996">
<CHAR_METHODS>
<P>Single centre<BR/>Concealment of randomization -Yes<BR/>Blinding of intervention - No<BR/>Completeness of followup -Yes (100%)<BR/>Blinding of outcome assessment -Yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Seventy-three infants less than 33 weeks GA, &gt; 500 gms, &lt; 2000 gms; &lt; 24 hours of age; with RDS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>HFJV ( Bunnell Life Pulse) 420/min; PIP decreased to 80-90% of CV (LVS) when switched over, PEEP unchanged. Protocol for CV was not specified.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>IVH grades 3 or 4; IVH all grades; periventricular echodensities (PVE); cystic periventricular leukomalacia (CPVL); supplemental oxygen at 28d and 36 wk; mortality at 28d and 36wk; days on MV and days in hospital.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Surfactant therapy used; backup use of the alternative intervention was allowed in both directions. Mean age at randomization 7.2+6 hrs., antenatal corticosteroids HFJV 22% CV 19%.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Paw = Mean airway pressure, PEEP = positive end expiratory pressure, PIP = peak inspiratory pressure, HVS = high volume strategy, ALS = air leak syndrome</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Carlo-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention commenced early but was only for 48 hours and then all the patients were switched back to conventional ventilation. The trial is therefore not comparable to trials where the intervention was intended to be used until extubation or failure to ventilate adequately. Infants with birth weights &lt; 1000 gms, who are of most interest in this review because of their high rate of CLD, IVH and PVL, were excluded from the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Keszler-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients who developed pulmonary interstitial emphysema on conventional ventilation were randomized. This trial thus fulfilled the definition of rescue therapy and is the subject of another review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Carlo-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Keszler-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wiswell-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Elective HFJV vs CV</NAME>
<DICH_OUTCOME CHI2="1.3536742653100284" CI_END="1.0853674035471605" CI_START="0.740293516555219" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8963762892481789" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.035576774427745546" LOG_CI_START="-0.13059605412532482" LOG_EFFECT_SIZE="-0.04750963984878966" METHOD="MH" NO="1" P_CHI2="0.5082219361697641" P_Q="0.0" P_Z="0.26240412843615135" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="100" WEIGHT="100.00000000000001" Z="1.1207269423395296">
<NAME>CLD at 28 d in survivors</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1934763390375072" CI_START="0.35016742725347544" EFFECT_SIZE="0.6464646464646465" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.07681381343300639" LOG_CI_START="-0.45572425466033173" LOG_EFFECT_SIZE="-0.18945522061366268" ORDER="374" O_E="0.0" SE="0.31281549730397845" STUDY_ID="STD-Carlo-1990" TOTAL_1="18" TOTAL_2="16" VAR="0.09785353535353536" WEIGHT="16.10503522016434"/>
<DICH_DATA CI_END="1.217438951598041" CI_START="0.7342333645127141" EFFECT_SIZE="0.9454545454545454" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" LOG_CI_END="0.08544719276237242" LOG_CI_START="-0.13416588448126185" LOG_EFFECT_SIZE="-0.024359345859444693" ORDER="375" O_E="0.0" SE="0.12900180867517572" STUDY_ID="STD-Keszler-1997" TOTAL_1="55" TOTAL_2="52" VAR="0.016641466641466644" WEIGHT="52.5964026660611"/>
<DICH_DATA CI_END="1.3051619574199984" CI_START="0.6806049131031535" EFFECT_SIZE="0.9424964936886395" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.11566440657817645" LOG_CI_START="-0.16710492017425707" LOG_EFFECT_SIZE="-0.025720256798040325" ORDER="376" O_E="0.0" SE="0.16610010226512145" STUDY_ID="STD-Wiswell-1996" TOTAL_1="31" TOTAL_2="32" VAR="0.0275892439724838" WEIGHT="31.298562113774565"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9705078197989492" CI_END="0.9916596801241234" CI_START="0.3504011650096099" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5894732455409235" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.003637344380367255" LOG_CI_START="-0.4554344585644482" LOG_EFFECT_SIZE="-0.22953590147240774" METHOD="MH" NO="2" P_CHI2="0.3245537679753152" P_Q="0.0" P_Z="0.04642345424865901" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="84" WEIGHT="100.0" Z="1.991522680959635">
<NAME>CLD at 36 w in survivors</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9236019206294648" CI_START="0.2655481387564715" EFFECT_SIZE="0.49523809523809526" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="-0.03451517263889001" LOG_CI_START="-0.5758567382313878" LOG_EFFECT_SIZE="-0.3051859554351389" ORDER="377" O_E="0.0" SE="0.3179867153130003" STUDY_ID="STD-Keszler-1997" TOTAL_1="55" TOTAL_2="52" VAR="0.10111555111555111" WEIGHT="75.80950991831972"/>
<DICH_DATA CI_END="2.3390378065234114" CI_START="0.3346923209745024" EFFECT_SIZE="0.8847926267281107" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3690372414892741" LOG_CI_START="-0.47535425177923385" LOG_EFFECT_SIZE="-0.05315850514497987" ORDER="378" O_E="0.0" SE="0.49599974295122423" STUDY_ID="STD-Wiswell-1996" TOTAL_1="31" TOTAL_2="32" VAR="0.24601574500768053" WEIGHT="24.19049008168028"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1401776549215067" CI_END="1.2231757201128266" CI_START="0.554458922695886" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8235294117647058" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.08748885179792405" LOG_CI_START="-0.25613062319799584" LOG_EFFECT_SIZE="-0.08432088570003592" METHOD="MH" NO="3" P_CHI2="0.7081045783815483" P_Q="0.0" P_Z="0.3360936733870933" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="86" WEIGHT="100.00000000000001" Z="0.9619122962605728">
<NAME>Air leak syndromes</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6668255615532803" CI_START="0.4958204985898988" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.22189015194627754" LOG_CI_START="-0.30467552226272765" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="379" O_E="0.0" SE="0.30930728357249476" STUDY_ID="STD-Carlo-1990" TOTAL_1="21" TOTAL_2="21" VAR="0.09567099567099568" WEIGHT="32.352941176470594"/>
<DICH_DATA CI_END="1.3059973243464529" CI_START="0.4689721480225026" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.11594228718196374" LOG_CI_START="-0.3288529490105373" LOG_EFFECT_SIZE="-0.10645533091428679" ORDER="380" O_E="0.0" SE="0.26127492351140397" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" VAR="0.06826458565589" WEIGHT="67.64705882352942"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7902805360070868" CI_START="0.07069359050308222" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23636363636363633" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.10221871426324758" LOG_CI_START="-1.1506199601115665" LOG_EFFECT_SIZE="-0.6264193371874072" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.01917272806141778" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="52" WEIGHT="100.0" Z="2.3421554389957304">
<NAME>Home oxygen in survivors</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7902805360070868" CI_START="0.07069359050308222" EFFECT_SIZE="0.23636363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.10221871426324758" LOG_CI_START="-1.1506199601115665" LOG_EFFECT_SIZE="-0.626419337187407" ORDER="381" O_E="0.0" SE="0.6158360814811675" STUDY_ID="STD-Keszler-1997" TOTAL_1="55" TOTAL_2="52" VAR="0.3792540792540792" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1534069222341616" CI_END="1.5040543590770648" CI_START="0.4891838068443698" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8577639751552797" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.1772635326788891" LOG_CI_START="-0.3105279275853258" LOG_EFFECT_SIZE="-0.06663219745321833" METHOD="MH" NO="5" P_CHI2="0.5617473209570216" P_Q="0.0" P_Z="0.5923309633294438" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="122" WEIGHT="100.0" Z="0.5354612282401624">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.195588890534318" CI_START="0.16396512186413478" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34155102462740894" LOG_CI_START="-0.7852485238601217" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="382" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Carlo-1990" TOTAL_1="21" TOTAL_2="21" VAR="0.4380952380952381" WEIGHT="22.670807453416153"/>
<DICH_DATA CI_END="1.6273149594677339" CI_START="0.3636149061917927" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2114716168095882" LOG_CI_START="-0.4393583214232617" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="383" O_E="0.0" SE="0.38230072737812854" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" VAR="0.14615384615384616" WEIGHT="58.944099378881994"/>
<DICH_DATA CI_END="4.744953290483623" CI_START="0.4489026094477314" EFFECT_SIZE="1.4594594594594594" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6762319415715178" LOG_CI_START="-0.3478478700595707" LOG_EFFECT_SIZE="0.1641920357559735" ORDER="384" O_E="0.0" SE="0.6015495506289251" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.3618618618618618" WEIGHT="18.385093167701864"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.240930199651372" CI_END="1.3453199146825514" CI_START="0.8564824905497831" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0734258014010718" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="56" I2="19.41529021689206" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.12882557107485432" LOG_CI_START="-0.06728151108181973" LOG_EFFECT_SIZE="0.03077202999651728" METHOD="MH" NO="6" P_CHI2="0.26529194035685943" P_Q="0.0" P_Z="0.5384931478658423" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="95" WEIGHT="100.0" Z="0.6150932425395583">
<NAME>IVH all grades</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.30869932284108" CI_START="0.7148328061494121" EFFECT_SIZE="0.9672131147540983" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" LOG_CI_END="0.11683987769618324" LOG_CI_START="-0.14579552443342894" LOG_EFFECT_SIZE="-0.01447782336862286" ORDER="385" O_E="0.0" SE="0.15427333527714193" STUDY_ID="STD-Keszler-1997" TOTAL_1="61" TOTAL_2="59" VAR="0.023800261977533443" WEIGHT="62.56849796262471"/>
<DICH_DATA CI_END="1.7551400966694066" CI_START="0.8916177472625515" EFFECT_SIZE="1.250965250965251" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.24431178791415917" LOG_CI_START="-0.04982129566343862" LOG_EFFECT_SIZE="0.09724524612536029" ORDER="386" O_E="0.0" SE="0.17277522927572647" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.029851279851279847" WEIGHT="37.431502037375296"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2410584515532104" CI_END="2.365886928409134" CI_START="0.7932427980631149" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3699353148934479" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="19.423617900633182" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.3739939847799032" LOG_CI_START="-0.10059386221607432" LOG_EFFECT_SIZE="0.13670006128191445" METHOD="MH" NO="7" P_CHI2="0.26526724534249335" P_Q="0.0" P_Z="0.25885810910484697" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="95" WEIGHT="99.99999999999999" Z="1.129094217194489">
<NAME>IVH grades 3 or 4</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.267027473600511" CI_START="0.4126554354749632" EFFECT_SIZE="0.9672131147540983" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3554567832764076" LOG_CI_START="-0.38441243001365344" LOG_EFFECT_SIZE="-0.01447782336862286" ORDER="387" O_E="0.0" SE="0.43460283829825425" STUDY_ID="STD-Keszler-1997" TOTAL_1="61" TOTAL_2="59" VAR="0.1888796270568985" WEIGHT="53.014008492400485"/>
<DICH_DATA CI_END="3.7670618211066347" CI_START="0.8834894138646502" EFFECT_SIZE="1.8243243243243243" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5760027474517864" LOG_CI_START="-0.05379864992372651" LOG_EFFECT_SIZE="0.2611020487640299" ORDER="388" O_E="0.0" SE="0.3699484583855727" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.13686186186186183" WEIGHT="46.9859915075995"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8567996567007163" CI_START="0.6548650772094772" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1027027027027028" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.2687650471521922" LOG_CI_START="-0.18384816910642227" LOG_EFFECT_SIZE="0.04245843902288498" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.7130835248329124" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0" Z="0.36771799114719617">
<NAME>Periventricular echodensities</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8567996567007163" CI_START="0.6548650772094772" EFFECT_SIZE="1.1027027027027028" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.2687650471521922" LOG_CI_START="-0.18384816910642227" LOG_EFFECT_SIZE="0.04245843902288498" ORDER="389" O_E="0.0" SE="0.26586724370186443" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.07068539127362657" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.153373701185641" CI_END="2.6072182059293847" CI_START="0.5878692095955843" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2380239520958085" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="86.02058215084926" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.4161773801001776" LOG_CI_START="-0.23071928594617547" LOG_EFFECT_SIZE="0.09272904707700104" METHOD="MH" NO="9" P_CHI2="0.0074823322616967" P_Q="0.0" P_Z="0.5741842105213945" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="93" TOTAL_2="90" WEIGHT="100.00000000000001" Z="0.5618999204383545">
<NAME>Periventricular leukomalacia</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2972400685790508" CI_START="0.13766100200855486" EFFECT_SIZE="0.4225865209471767" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.11302035450450502" LOG_CI_START="-0.8611890736228895" LOG_EFFECT_SIZE="-0.3740843595591922" ORDER="390" O_E="0.0" SE="0.5722554404964757" STUDY_ID="STD-Keszler-1997" TOTAL_1="61" TOTAL_2="58" VAR="0.32747628917781546" WEIGHT="82.18562874251498"/>
<DICH_DATA CI_END="21.038910015552133" CI_START="1.188274486725776" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.323023236123662" LOG_CI_START="0.07491677254837557" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="391" O_E="0.0" SE="0.733143914930759" STUDY_ID="STD-Wiswell-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.5375" WEIGHT="17.814371257485032"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0647277124905883" CI_END="2.216506901490713" CI_START="-15.941673750904904" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.862583424707096" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.9681542493018926" P_Q="1.0" P_Z="0.13848089220507692" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="122" UNITS="" WEIGHT="100.0" Z="1.4814718072047521">
<NAME>Days in oxygen</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<CONT_DATA CI_END="31.44023792116787" CI_START="-45.44023792116787" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="46.0" ORDER="392" SD_1="45.0" SD_2="77.8" SE="19.61272667476523" STUDY_ID="STD-Carlo-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="5.578437088531906"/>
<CONT_DATA CI_END="4.049125450191752" CI_START="-19.64912545019176" EFFECT_SIZE="-7.800000000000004" ESTIMABLE="YES" MEAN_1="45.3" MEAN_2="53.1" ORDER="393" SD_1="29.5" SD_2="38.8" SE="6.045583257476232" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" WEIGHT="58.709999768081964"/>
<CONT_DATA CI_END="9.892803006247416" CI_START="-20.492803006247424" EFFECT_SIZE="-5.300000000000004" ESTIMABLE="YES" MEAN_1="46.8" MEAN_2="52.1" ORDER="394" SD_1="36.7" SD_2="29.2" SE="7.75157254219277" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" WEIGHT="35.71156314338612"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8038975969626727" CI_END="2.64231967869633" CI_START="-13.540853228347073" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.449266774825372" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.36993065476229026" P_Q="1.0" P_Z="0.18685678448214157" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="101" UNITS="" WEIGHT="100.0" Z="1.3199348090954461">
<NAME>Days in hospital</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.323878204371097" CI_START="-12.923878204371091" EFFECT_SIZE="-2.299999999999997" ESTIMABLE="YES" MEAN_1="79.4" MEAN_2="81.7" ORDER="395" SD_1="33.3" SD_2="28.3" SE="5.420445624598661" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" WEIGHT="58.00977633566175"/>
<CONT_DATA CI_END="2.687042351223134" CI_START="-22.287042351223157" EFFECT_SIZE="-9.800000000000011" ESTIMABLE="YES" MEAN_1="66.1" MEAN_2="75.9" ORDER="396" SD_1="33.8" SD_2="18.7" SE="6.371057044782119" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" WEIGHT="41.990223664338245"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3546954465462044" CI_END="7.331163030151787" CI_START="-4.875974629169804" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2275942004909914" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="0.8374885567655088" P_Q="1.0" P_Z="0.6934317431341457" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="123" TOTAL_2="122" UNITS="" WEIGHT="100.0" Z="0.39420222622873263">
<NAME>Days on IPPV</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.878822747849835" CI_START="-8.878822747849835" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="13.0" ORDER="397" SD_1="27.0" SD_2="18.0" SE="7.081162132224988" STUDY_ID="STD-Carlo-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="19.340265620551456"/>
<CONT_DATA CI_END="8.367594008815862" CI_START="-7.9675940088158566" EFFECT_SIZE="0.20000000000000284" ESTIMABLE="YES" MEAN_1="29.1" MEAN_2="28.9" ORDER="398" SD_1="25.9" SD_2="21.4" SE="4.167216373995032" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" WEIGHT="55.84437170331822"/>
<CONT_DATA CI_END="12.852466762344843" CI_START="-11.652466762344854" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" MEAN_1="33.8" MEAN_2="33.2" ORDER="399" SD_1="30.5" SD_2="22.4" SE="6.251373422670387" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" WEIGHT="24.815362676130324"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Elective HFJV vs CV with surfactant replacement therapy</NAME>
<DICH_OUTCOME CHI2="2.220189598945748E-4" CI_END="1.153079099308194" CI_START="0.773406431855046" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9443509897504109" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.061859100195640566" LOG_CI_START="-0.11159222053869702" LOG_EFFECT_SIZE="-0.02486656017152822" METHOD="MH" NO="1" P_CHI2="0.9881117200930368" P_Q="0.0" P_Z="0.5741337670185311" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="84" WEIGHT="100.0" Z="0.5619739549892636">
<NAME>CLD at 28 d in survivors</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.217438951598041" CI_START="0.7342333645127141" EFFECT_SIZE="0.9454545454545454" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" LOG_CI_END="0.08544719276237242" LOG_CI_START="-0.13416588448126185" LOG_EFFECT_SIZE="-0.024359345859444693" ORDER="400" O_E="0.0" SE="0.12900180867517572" STUDY_ID="STD-Keszler-1997" TOTAL_1="55" TOTAL_2="52" VAR="0.016641466641466644" WEIGHT="62.69315781237775"/>
<DICH_DATA CI_END="1.3051619574199984" CI_START="0.6806049131031535" EFFECT_SIZE="0.9424964936886395" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.11566440657817645" LOG_CI_START="-0.16710492017425707" LOG_EFFECT_SIZE="-0.025720256798040325" ORDER="401" O_E="0.0" SE="0.16610010226512145" STUDY_ID="STD-Wiswell-1996" TOTAL_1="31" TOTAL_2="32" VAR="0.0275892439724838" WEIGHT="37.30684218762226"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9705078197989492" CI_END="0.9916596801241234" CI_START="0.3504011650096099" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5894732455409235" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.003637344380367255" LOG_CI_START="-0.4554344585644482" LOG_EFFECT_SIZE="-0.22953590147240774" METHOD="MH" NO="2" P_CHI2="0.3245537679753152" P_Q="0.0" P_Z="0.04642345424865901" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="84" WEIGHT="100.0" Z="1.991522680959635">
<NAME>CLD at 36 w in survivors</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9236019206294648" CI_START="0.2655481387564715" EFFECT_SIZE="0.49523809523809526" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="21" LOG_CI_END="-0.03451517263889001" LOG_CI_START="-0.5758567382313878" LOG_EFFECT_SIZE="-0.3051859554351389" ORDER="402" O_E="0.0" SE="0.3179867153130003" STUDY_ID="STD-Keszler-1997" TOTAL_1="55" TOTAL_2="52" VAR="0.10111555111555111" WEIGHT="75.80950991831972"/>
<DICH_DATA CI_END="2.3390378065234114" CI_START="0.3346923209745024" EFFECT_SIZE="0.8847926267281107" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3690372414892741" LOG_CI_START="-0.47535425177923385" LOG_EFFECT_SIZE="-0.05315850514497987" ORDER="403" O_E="0.0" SE="0.49599974295122423" STUDY_ID="STD-Wiswell-1996" TOTAL_1="31" TOTAL_2="32" VAR="0.24601574500768053" WEIGHT="24.19049008168028"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3059973243464529" CI_START="0.4689721480225026" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.11594228718196374" LOG_CI_START="-0.3288529490105373" LOG_EFFECT_SIZE="-0.10645533091428679" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.348152810331504" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.9381782787979115">
<NAME>Air leak syndromes</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3059973243464529" CI_START="0.4689721480225026" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.11594228718196374" LOG_CI_START="-0.3288529490105373" LOG_EFFECT_SIZE="-0.10645533091428679" ORDER="404" O_E="0.0" SE="0.26127492351140397" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" VAR="0.06826458565589" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.7902805360070868" CI_START="0.07069359050308222" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.23636363636363633" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.10221871426324758" LOG_CI_START="-1.1506199601115665" LOG_EFFECT_SIZE="-0.6264193371874072" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.01917272806141778" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="52" WEIGHT="100.0" Z="2.3421554389957304">
<NAME>Home oxygen in survivors</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7902805360070868" CI_START="0.07069359050308222" EFFECT_SIZE="0.23636363636363636" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.10221871426324758" LOG_CI_START="-1.1506199601115665" LOG_EFFECT_SIZE="-0.626419337187407" ORDER="405" O_E="0.0" SE="0.6158360814811675" STUDY_ID="STD-Keszler-1997" TOTAL_1="55" TOTAL_2="52" VAR="0.3792540792540792" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8081584466006185" CI_END="1.745229204923075" CI_START="0.49913851352808847" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9333333333333335" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.24185247192354442" LOG_CI_START="-0.3017789186784307" LOG_EFFECT_SIZE="-0.02996322337744316" METHOD="MH" NO="5" P_CHI2="0.36866532303468014" P_Q="0.0" P_Z="0.8289457404104882" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="101" WEIGHT="100.00000000000003" Z="0.21605389127911714">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6273149594677339" CI_START="0.3636149061917927" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2114716168095882" LOG_CI_START="-0.4393583214232617" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="406" O_E="0.0" SE="0.38230072737812854" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" VAR="0.14615384615384616" WEIGHT="76.22489959839359"/>
<DICH_DATA CI_END="4.744953290483623" CI_START="0.4489026094477314" EFFECT_SIZE="1.4594594594594594" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6762319415715178" LOG_CI_START="-0.3478478700595707" LOG_EFFECT_SIZE="0.1641920357559735" ORDER="407" O_E="0.0" SE="0.6015495506289251" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.3618618618618618" WEIGHT="23.77510040160643"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9509762837959239" CI_END="1.4291512989777997" CI_START="0.8371252762277976" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0937909653714033" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.15507820838012695" LOG_CI_START="-0.0772095447507756" LOG_EFFECT_SIZE="0.03893433181467567" METHOD="MH" NO="6" P_CHI2="0.32947109483124937" P_Q="0.0" P_Z="0.5111623123657159" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="95" WEIGHT="100.00000000000003" Z="0.6570289400999365">
<NAME>IVH all grades</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4561914916879286" CI_START="0.6424300750912564" EFFECT_SIZE="0.9672131147540983" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" LOG_CI_END="0.16321848920440002" LOG_CI_START="-0.19217413594164573" LOG_EFFECT_SIZE="-0.01447782336862286" ORDER="408" O_E="0.0" SE="0.2087593872326541" STUDY_ID="STD-Keszler-1997" TOTAL_1="61" TOTAL_2="59" VAR="0.043580481757753226" WEIGHT="55.391401697461475"/>
<DICH_DATA CI_END="1.7551400966694066" CI_START="0.8916177472625515" EFFECT_SIZE="1.250965250965251" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.24431178791415917" LOG_CI_START="-0.04982129566343862" LOG_EFFECT_SIZE="0.09724524612536029" ORDER="409" O_E="0.0" SE="0.17277522927572647" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.029851279851279847" WEIGHT="44.608598302538546"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2410584515532104" CI_END="2.365886928409134" CI_START="0.7932427980631149" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3699353148934479" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="17" I2="19.423617900633182" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.3739939847799032" LOG_CI_START="-0.10059386221607432" LOG_EFFECT_SIZE="0.13670006128191445" METHOD="MH" NO="7" P_CHI2="0.26526724534249335" P_Q="0.0" P_Z="0.25885810910484697" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="95" WEIGHT="99.99999999999999" Z="1.129094217194489">
<NAME>IVH grades 3 or 4</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.267027473600511" CI_START="0.4126554354749632" EFFECT_SIZE="0.9672131147540983" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3554567832764076" LOG_CI_START="-0.38441243001365344" LOG_EFFECT_SIZE="-0.01447782336862286" ORDER="410" O_E="0.0" SE="0.43460283829825425" STUDY_ID="STD-Keszler-1997" TOTAL_1="61" TOTAL_2="59" VAR="0.1888796270568985" WEIGHT="53.014008492400485"/>
<DICH_DATA CI_END="3.7670618211066347" CI_START="0.8834894138646502" EFFECT_SIZE="1.8243243243243243" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5760027474517864" LOG_CI_START="-0.05379864992372651" LOG_EFFECT_SIZE="0.2611020487640299" ORDER="411" O_E="0.0" SE="0.3699484583855727" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.13686186186186183" WEIGHT="46.9859915075995"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8567996567007163" CI_START="0.6548650772094772" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1027027027027028" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.2687650471521922" LOG_CI_START="-0.18384816910642227" LOG_EFFECT_SIZE="0.04245843902288498" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.7130835248329124" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0" Z="0.36771799114719617">
<NAME>Periventricular echodensities</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8567996567007163" CI_START="0.6548650772094772" EFFECT_SIZE="1.1027027027027028" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.2687650471521922" LOG_CI_START="-0.18384816910642227" LOG_EFFECT_SIZE="0.04245843902288498" ORDER="412" O_E="0.0" SE="0.26586724370186443" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.07068539127362657" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.153373701185641" CI_END="2.6072182059293847" CI_START="0.5878692095955843" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2380239520958085" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="86.02058215084926" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.4161773801001776" LOG_CI_START="-0.23071928594617547" LOG_EFFECT_SIZE="0.09272904707700104" METHOD="MH" NO="9" P_CHI2="0.0074823322616967" P_Q="0.0" P_Z="0.5741842105213945" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="93" TOTAL_2="90" WEIGHT="100.00000000000001" Z="0.5618999204383545">
<NAME>Periventricular leukomalacia</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2972400685790508" CI_START="0.13766100200855486" EFFECT_SIZE="0.4225865209471767" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.11302035450450502" LOG_CI_START="-0.8611890736228895" LOG_EFFECT_SIZE="-0.3740843595591922" ORDER="413" O_E="0.0" SE="0.5722554404964757" STUDY_ID="STD-Keszler-1997" TOTAL_1="61" TOTAL_2="58" VAR="0.32747628917781546" WEIGHT="82.18562874251498"/>
<DICH_DATA CI_END="21.038910015552133" CI_START="1.188274486725776" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.323023236123662" LOG_CI_START="0.07491677254837557" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="414" O_E="0.0" SE="0.733143914930759" STUDY_ID="STD-Wiswell-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.5375" WEIGHT="17.814371257485032"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.06467572113934046" CI_END="2.4889739443697367" CI_START="-16.197903618787965" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.854464837209114" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.10" NO="10" P_CHI2="0.7992528206141792" P_Q="1.0" P_Z="0.15047538093567828" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="101" UNITS="" WEIGHT="100.0" Z="1.4378543626478293">
<NAME>Days in oxygen</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.049125450191752" CI_START="-19.64912545019176" EFFECT_SIZE="-7.800000000000004" ESTIMABLE="YES" MEAN_1="45.3" MEAN_2="53.1" ORDER="415" SD_1="29.5" SD_2="38.8" SE="6.045583257476232" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" WEIGHT="62.17859348836437"/>
<CONT_DATA CI_END="9.892803006247416" CI_START="-20.492803006247424" EFFECT_SIZE="-5.300000000000004" ESTIMABLE="YES" MEAN_1="46.8" MEAN_2="52.1" ORDER="416" SD_1="36.7" SD_2="29.2" SE="7.75157254219277" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" WEIGHT="37.82140651163563"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8038975969626727" CI_END="2.64231967869633" CI_START="-13.540853228347073" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.449266774825372" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.11" NO="11" P_CHI2="0.36993065476229026" P_Q="1.0" P_Z="0.18685678448214157" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="101" UNITS="" WEIGHT="100.0" Z="1.3199348090954461">
<NAME>Days in hospital</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.323878204371097" CI_START="-12.923878204371091" EFFECT_SIZE="-2.299999999999997" ESTIMABLE="YES" MEAN_1="79.4" MEAN_2="81.7" ORDER="417" SD_1="33.3" SD_2="28.3" SE="5.420445624598661" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" WEIGHT="58.00977633566175"/>
<CONT_DATA CI_END="2.687042351223134" CI_START="-22.287042351223157" EFFECT_SIZE="-9.800000000000011" ESTIMABLE="YES" MEAN_1="66.1" MEAN_2="75.9" ORDER="418" SD_1="33.8" SD_2="18.7" SE="6.371057044782119" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" WEIGHT="41.990223664338245"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.002834599591444961" CI_END="7.119094548742957" CI_START="-6.47297062714023" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.32306196080136423" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.12" NO="12" P_CHI2="0.9575399449713715" P_Q="1.0" P_Z="0.9257681037396311" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="101" UNITS="" WEIGHT="100.00000000000001" Z="0.09317050790325115">
<NAME>Days on IPPV</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.367594008815862" CI_START="-7.9675940088158566" EFFECT_SIZE="0.20000000000000284" ESTIMABLE="YES" MEAN_1="29.1" MEAN_2="28.9" ORDER="419" SD_1="25.9" SD_2="21.4" SE="4.167216373995032" STUDY_ID="STD-Keszler-1997" TOTAL_1="65" TOTAL_2="65" WEIGHT="69.23450979965901"/>
<CONT_DATA CI_END="12.852466762344843" CI_START="-11.652466762344854" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" MEAN_1="33.8" MEAN_2="33.2" ORDER="420" SD_1="30.5" SD_2="22.4" SE="6.251373422670387" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" WEIGHT="30.765490200341006"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Elective HFJV with low volume strategy</NAME>
<DICH_OUTCOME CHI2="1.174715367121948" CI_END="1.1269813632166645" CI_START="0.6289653967297634" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8419217779714567" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" I2="14.872995792163719" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.05191673421905571" LOG_CI_START="-0.20137324711864807" LOG_EFFECT_SIZE="-0.0747282564497962" METHOD="MH" NO="1" P_CHI2="0.278434527516774" P_Q="0.0" P_Z="0.247477495489283" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.00000000000001" Z="1.1564981014688984">
<NAME>CLD at 28 d in survivors</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1934763390375072" CI_START="0.35016742725347544" EFFECT_SIZE="0.6464646464646465" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.07681381343300639" LOG_CI_START="-0.45572425466033173" LOG_EFFECT_SIZE="-0.18945522061366268" ORDER="421" O_E="0.0" SE="0.31281549730397845" STUDY_ID="STD-Carlo-1990" TOTAL_1="18" TOTAL_2="16" VAR="0.09785353535353536" WEIGHT="33.974289138250356"/>
<DICH_DATA CI_END="1.3051619574199984" CI_START="0.6806049131031535" EFFECT_SIZE="0.9424964936886395" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.11566440657817645" LOG_CI_START="-0.16710492017425707" LOG_EFFECT_SIZE="-0.025720256798040325" ORDER="422" O_E="0.0" SE="0.16610010226512145" STUDY_ID="STD-Wiswell-1996" TOTAL_1="31" TOTAL_2="32" VAR="0.0275892439724838" WEIGHT="66.02571086174966"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.3390378065234114" CI_START="0.3346923209745024" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8847926267281107" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.3690372414892741" LOG_CI_START="-0.47535425177923385" LOG_EFFECT_SIZE="-0.05315850514497987" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.8050797927900593" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="32" WEIGHT="100.0" Z="0.24677831642488318">
<NAME>CLD at 36 w in survivors</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3390378065234114" CI_START="0.3346923209745024" EFFECT_SIZE="0.8847926267281107" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3690372414892741" LOG_CI_START="-0.47535425177923385" LOG_EFFECT_SIZE="-0.05315850514497987" ORDER="423" O_E="0.0" SE="0.49599974295122423" STUDY_ID="STD-Wiswell-1996" TOTAL_1="31" TOTAL_2="32" VAR="0.24601574500768053" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.66682556155328" CI_START="0.49582049858989885" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.22189015194627748" LOG_CI_START="-0.3046755222627276" LOG_EFFECT_SIZE="-0.04139268515822506" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.7579752316198017" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="21" WEIGHT="100.00000000000001" Z="0.30814075473261954">
<NAME>Air leak syndromes</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6668255615532803" CI_START="0.4958204985898988" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.22189015194627754" LOG_CI_START="-0.30467552226272765" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="424" O_E="0.0" SE="0.30930728357249476" STUDY_ID="STD-Carlo-1990" TOTAL_1="21" TOTAL_2="21" VAR="0.09567099567099568" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Home oxygen in survivors</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9881027696068807" CI_END="2.3085876228838753" CI_START="0.4201580562205466" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9848714069591529" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.3633463629299455" LOG_CI_START="-0.37658730476484203" LOG_EFFECT_SIZE="-0.006620470917448256" METHOD="MH" NO="5" P_CHI2="0.320206749672442" P_Q="0.0" P_Z="0.9720214495774004" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="57" WEIGHT="100.0" Z="0.035073102158789206">
<NAME>Neonatal mortality</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.195588890534318" CI_START="0.16396512186413478" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34155102462740894" LOG_CI_START="-0.7852485238601217" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="425" O_E="0.0" SE="0.6618876325292973" STUDY_ID="STD-Carlo-1990" TOTAL_1="21" TOTAL_2="21" VAR="0.4380952380952381" WEIGHT="55.21936459909228"/>
<DICH_DATA CI_END="4.744953290483623" CI_START="0.4489026094477314" EFFECT_SIZE="1.4594594594594594" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6762319415715178" LOG_CI_START="-0.3478478700595707" LOG_EFFECT_SIZE="0.1641920357559735" ORDER="426" O_E="0.0" SE="0.6015495506289251" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.3618618618618618" WEIGHT="44.78063540090772"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7551400966694066" CI_START="0.8916177472625515" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.250965250965251" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.24431178791415917" LOG_CI_START="-0.04982129566343862" LOG_EFFECT_SIZE="0.09724524612536029" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.19497796359432007" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0" Z="1.2959928054006635">
<NAME>IVH all grades</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7551400966694066" CI_START="0.8916177472625515" EFFECT_SIZE="1.250965250965251" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.24431178791415917" LOG_CI_START="-0.04982129566343862" LOG_EFFECT_SIZE="0.09724524612536029" ORDER="427" O_E="0.0" SE="0.17277522927572647" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.029851279851279847" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.7670618211066347" CI_START="0.8834894138646502" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8243243243243243" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.5760027474517864" LOG_CI_START="-0.05379864992372651" LOG_EFFECT_SIZE="0.2611020487640299" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.10413754118540682" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0" Z="1.625117422729354">
<NAME>IVH grades 3 or 4</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7670618211066347" CI_START="0.8834894138646502" EFFECT_SIZE="1.8243243243243243" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5760027474517864" LOG_CI_START="-0.05379864992372651" LOG_EFFECT_SIZE="0.2611020487640299" ORDER="428" O_E="0.0" SE="0.3699484583855727" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.13686186186186183" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8567996567007163" CI_START="0.6548650772094772" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1027027027027028" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.2687650471521922" LOG_CI_START="-0.18384816910642227" LOG_EFFECT_SIZE="0.04245843902288498" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.7130835248329124" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0" Z="0.36771799114719617">
<NAME>Periventricular echodensities</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8567996567007163" CI_START="0.6548650772094772" EFFECT_SIZE="1.1027027027027028" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.2687650471521922" LOG_CI_START="-0.18384816910642227" LOG_EFFECT_SIZE="0.04245843902288498" ORDER="429" O_E="0.0" SE="0.26586724370186443" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" VAR="0.07068539127362657" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.038910015552133" CI_START="1.188274486725776" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="1.323023236123662" LOG_CI_START="0.07491677254837557" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" NO="9" P_CHI2="1.0" P_Q="0.0" P_Z="0.02814530433834212" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.195255092018464">
<NAME>Periventricular leukomalacia</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.038910015552133" CI_START="1.188274486725776" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.323023236123662" LOG_CI_START="0.07491677254837557" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="430" O_E="0.0" SE="0.733143914930759" STUDY_ID="STD-Wiswell-1996" TOTAL_1="32" TOTAL_2="32" VAR="0.5375" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.006498092148400267" CI_END="8.599599020626872" CI_START="-19.65895203575103" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.52967650756208" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" NO="10" P_CHI2="0.9357515212119585" P_Q="1.0" P_Z="0.44304733398163554" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="0.7670575026551332">
<NAME>Days in oxygen</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<CONT_DATA CI_END="31.44023792116787" CI_START="-45.44023792116787" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="46.0" ORDER="431" SD_1="45.0" SD_2="77.8" SE="19.61272667476523" STUDY_ID="STD-Carlo-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="13.510382797769175"/>
<CONT_DATA CI_END="9.892803006247416" CI_START="-20.492803006247424" EFFECT_SIZE="-5.300000000000004" ESTIMABLE="YES" MEAN_1="46.8" MEAN_2="52.1" ORDER="432" SD_1="36.7" SD_2="29.2" SE="7.75157254219277" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" WEIGHT="86.48961720223082"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="46.02071602402053" CI_START="19.779283975979457" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="32.89999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="8.897276319895636E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="4.91458049799393">
<NAME>Days in hospital</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<CONT_DATA CI_END="46.02071602402053" CI_START="19.779283975979457" EFFECT_SIZE="32.89999999999999" ESTIMABLE="YES" MEAN_1="66.1" MEAN_2="33.2" ORDER="433" SD_1="33.8" SD_2="22.4" SE="6.694365879942217" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.21698556061608776" CI_END="11.712456429330995" CI_START="-6.65803641480156" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.527210007264718" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.12" NO="12" P_CHI2="0.6413464474087034" P_Q="1.0" P_Z="0.5897071210630147" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="0.5392605018966703">
<NAME>Days on IPPV</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.878822747849835" CI_START="-8.878822747849835" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="13.0" ORDER="434" SD_1="27.0" SD_2="18.0" SE="7.081162132224988" STUDY_ID="STD-Carlo-1990" TOTAL_1="21" TOTAL_2="21" WEIGHT="43.800227437834565"/>
<CONT_DATA CI_END="12.852466762344843" CI_START="-11.652466762344854" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" MEAN_1="33.8" MEAN_2="33.2" ORDER="435" SD_1="30.5" SD_2="22.4" SE="6.251373422670387" STUDY_ID="STD-Wiswell-1996" TOTAL_1="37" TOTAL_2="36" WEIGHT="56.199772562165435"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>